Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E<sub>2</sub> and down-regulating the Wnt pathway activity.

导出 OA

翻译打印收藏纠错

作者： Chaolin,Huang ^[1] ; Yuanhong,Chen ^[1] ; Hang,Liu ^[1] ; Jing,Yang ^[1] ; Xuejing,Song ^[1] ; Junping,Zhao ^[1] ; Na,He ^[1] ; Chengji J,Zhou ^[2] ; Yongping,Wang ^[2] ; Changjiang,Huang ^[1] ; Qiaoxiang,Dong ^[1]

作者单位： Institute of Environmental Safety and Human Health, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou 325035, P.R. China. ^[1] Department of Biochemistry and Molecular Medicine, University of California at Davis, School of Medicine, Sacramento, CA 95817, USA. ^[2]

关键词 CSCs EMT PGE2 Wnt pathway celecoxib

DOI 10.18632/oncotarget.23250

PMID 29383157

发布时间 2022-04-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览12

Oncotarget

2017年8卷70期

115254-115269页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E<sub>2</sub> and down-regulating the Wnt pathway activity.

Oncotarget

相似文献

Oncotarget

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E<sub>2</sub> and down-regulating the Wnt pathway activity.

Oncotarget

相似文献

Oncotarget

相关期刊

检索历史清除